CoChat

TGFβ1 in liver fibrosis: time to change paradigms?

Bauer, Michael, Schuppan, Detlef · 2001 · FEBS Letters
Cited by 84

The DOI matches its Crossref record.

Abstract

Chronic tissue damage often results in a deregulated wound healing, characterized by an imbalance between extracellular matrix (ECM) synthesis (fibrogenesis) and degradation (fibrolysis), that leads to scar formation. Excessive scarring finally results in architectural distortion and failure of organs such as lungs, kidneys and liver. Hepatic stellate cells (HSC) have been identified as an important cellular source of ECM in liver fibrosis [1]. These cells reside in the perisinusoidal space of Disse that separates hepatocytes from the sinusoidal endothelium. Upon injury (e.g. by toxins or chronic hepatitis) the normally quiescent HSC become activated and start to proliferate. The activated HSC undergo a phenotypic transdifferentiation to contractile myofibroblasts (MFB) that express α-smooth muscle actin and an excess of ECM molecules. Cytokines of the transforming growth factor (TGF) family influence a wide spectrum of cellular processes including differentiation, proliferation, apoptosis and migration. In most cells TGFβ1 has anti-proliferative activity and is the most potent single profibrogenic factor known. TGFβ1 participates in initiation and maintenance of fibrogenesis in many organs including the liver. Accordingly, tissue and serum levels of active TGFβ1 are elevated in fibrosis, and overexpression of TGFβ1 in transgenic mice and application of exogenous TGFβ1 can induce organ fibrosis [2, 3]. Furthermore, experimental fibrosis can be inhibited by anti-TGFβ1 treatments, e.g. with neutralizing antibodies or soluble TGFβ receptors [4, 5]. The observed TGFβ1 expression of activated HSC/MFB, the potency of TGFβ1 to upregulate ECM expression, and the expression of TGFβ receptors on HSC has led to a widely accepted model in which persistent auto-/paracrine stimulation of activated HSC/MFB by TGFβ1 is the key fibrogenic response in liver fibrosis. Other cellular sources for TGFβ1 in liver are hepatocytes, (sinusoidal) endothelial cells, platelets, and infiltrating mononuclear cells. Since specific inhibition of TGFβ1 seems to be a promising target for an anti-fibrotic therapy, the underlying molecular mechanisms of the profibrogenic effects of TGFβ1 are the focus of intense investigations. TGFβ1 is synthesized as a precursor (latent TGFβ1) that has to undergo specific proteolysis, e.g. by plasmin, and dissociation from the latency-associated peptide moiety for activation. Our understanding of TGFβ-dependent signal transduction has been revolutionized in the past few years (see [6] for review). Binding of active TGFβ1 to the cellular, constitutively phosphorylated TGFβ type II receptor (TGFβRII) induces formation of heterotetrameric complexes with type I receptors (TGFβRI) (Fig. 1A ). Upon phosphorylation of serine and threonine residues in TGFβRI by ligand-activated TGFβRII the thereby activated serine/threonine kinase domain of TGFβRI phosphorylates the TGFβ-specific signal transducers Smad2 and Smad3. Whereas Smad2 requires presentation to TGFβRI by the adapter protein Smad anchor for receptor activation (SARA), Smad3 works SARA-independent. Phosphorylated Smad2 and Smad3 dissociate from the (receptor) complex and form heterodimeric complexes with Smad4 or heterotrimeric complexes with Smad3 and Smad4. These complexes translocate into the nucleus where they act as transcriptional modulators on TGFβ responsive gene promoters, e.g. those for plasminogen activator inhibitor 1 (PAI-1), the α2 chain of collagen I, and Smad7 [7]. Smad2 seems to be the main signaling molecule for TGFβ1-induced ECM upregulation, since fibroblasts from Smad3 knockout mice still increase their ECM molecule production upon TGFβ1 treatment. A Smad2 gene inactivation is embryonically lethal [7]. The third TGFβ receptor (TGFβRIII or betaglycan) is a proteoglycan that binds TGFβ1 with high affinity, serving as a non-signaling co-receptor for TGFβRI and TGFβRII. Expression of TGFβRIII on the cell surface seems to be downregulated during transdifferentiation of HSC to MFB [8]. Stimulation by TGFβ1 requires binding of the cytokine to its cognate receptors on activated HSC/MFB and subsequent signal transduction to the nucleus. Investigations of the binding properties of HSC and MFB for TGFβ1 led to divergent results. Using HSC isolated from liver subsequent to injection of the hepatotoxin CCl4, constant cellular TGFβ1 binding within the following 72 h was observed [9]. Cells exhibited an increased secretion of the ECM protein fibronectin and its synthesis could be further stimulated by exogenous TGFβ1. HSC cultured on plastic undergo spontaneous activation and start to transdifferentiate to MFB within 3–5 days. Using 5 day old culture-activated cells Friedman et al. found elevated and saturable TGFβ1 binding compared to HSCs maintained in suspension to prevent spontaneous activation [10]. Fibronectin mRNA expression was only inducible by TGFβ1 in culture-activated HSC, whereas suspension cultured cells showed no response. However, how far

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0014-5793(01)02655-2

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 84

Metadata

Authors
Bauer, M., & Schuppan, D.
Venue
FEBS Letters
Publisher
Wiley
Published
2001-07-24
Volume
502
Issue
1-2
Pages
1-3
ISSN
  • 0014-5793 (ISSN-L)
  • 1873-3468
OpenAlex
W2023686103
Cited by
84
References
0
FWCI
2.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TGFβ1 in liver fibrosis: time to change paradigms? https://app.cochat.ai/papers/10.1016/s0014-5793(01)02655-2
The paper
Bauer, M., & Schuppan, D. (2001). TGFβ1 in liver fibrosis: time to change paradigms? FEBS Letters. https://doi.org/10.1016/s0014-5793(01)02655-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.